Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Venrock Healthcare Capital Par Purchases 52,939 Shares of Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 52,939 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was bought at an average price of $25.91 per share, for a total transaction of $1,371,649.49. Following the transaction, the insider directly owned 52,939 shares in the company, valued at $1,371,649.49. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $26.62 per share, with a total value of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The shares were bought at an average cost of $18.04 per share, with a total value of $35,226,798.20.

Lycia Therapeutics Price Performance

Lycia Therapeutics stock opened at $26.11 on Wednesday. Lycia Therapeutics, Inc. has a twelve month low of $22.19 and a twelve month high of $36.49.

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.